SG Americas Securities LLC purchased a new position in STAAR Surgical (NASDAQ:STAA) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 77,891 shares of the medical instruments supplier’s stock, valued at approximately $2,486,000. SG Americas Securities LLC owned approximately 0.18% of STAAR Surgical at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also made changes to their positions in the company. First Quadrant L P CA purchased a new stake in shares of STAAR Surgical during the fourth quarter valued at approximately $92,000. Bank of Montreal Can boosted its holdings in STAAR Surgical by 903.3% in the fourth quarter. Bank of Montreal Can now owns 3,050 shares of the medical instruments supplier’s stock worth $97,000 after purchasing an additional 2,746 shares during the last quarter. Winslow Evans & Crocker Inc. purchased a new position in shares of STAAR Surgical during the 3rd quarter worth $142,000. Harvest Fund Management Co. Ltd purchased a new position in shares of STAAR Surgical during the 3rd quarter worth $222,000. Finally, Xact Kapitalforvaltning AB boosted its stake in shares of STAAR Surgical by 31.0% during the 4th quarter. Xact Kapitalforvaltning AB now owns 7,600 shares of the medical instruments supplier’s stock worth $243,000 after acquiring an additional 1,800 shares during the last quarter. 85.79% of the stock is owned by institutional investors and hedge funds.
Several analysts have recently commented on STAA shares. BidaskClub downgraded shares of STAAR Surgical from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, November 20th. Zacks Investment Research upgraded shares of STAAR Surgical from a “hold” rating to a “buy” rating and set a $45.00 price target on the stock in a report on Tuesday, October 23rd. ValuEngine downgraded shares of STAAR Surgical from a “strong-buy” rating to a “buy” rating in a report on Friday, December 21st. Finally, TheStreet downgraded shares of STAAR Surgical from a “b-” rating to a “c” rating in a report on Friday, December 14th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. STAAR Surgical presently has a consensus rating of “Buy” and a consensus price target of $45.25.
Shares of NASDAQ STAA opened at $34.08 on Monday. STAAR Surgical has a 52-week low of $13.60 and a 52-week high of $54.00. The firm has a market capitalization of $1.50 billion, a price-to-earnings ratio of 3,408.00 and a beta of 1.99. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.76 and a current ratio of 5.35.
COPYRIGHT VIOLATION WARNING: This piece was reported by Zolmax and is owned by of Zolmax. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://zolmax.com/investing/sg-americas-securities-llc-acquires-new-position-in-staar-surgical-staa/2891577.html.
About STAAR Surgical
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.
Featured Article: What are the components of an earnings report?
Want to see what other hedge funds are holding STAA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STAAR Surgical (NASDAQ:STAA).
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.